By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


RedHill Biopharma Ltd. 

21 Ha’arba’a Street

Tel-Aviv    64739  Israel
Phone: 972-0-3-541-3131 Fax: 972-0-3-541-3144



Company News
RedHill Biopharma (RDHL) Announces Allowance Of A Patent In Japan Supporting RHB-104 For Multiple Sclerosis 10/18/2016 11:54:29 AM
RedHill Biopharma (RDHL) To Host Webcast Today At 8:30 Am EDT Following Announcement Of Progress Update On RHB-104 Phase III Crohn’s Disease Program 10/6/2016 10:50:21 AM
RedHill Biopharma (RDHL) Provides Progress Update On RHB-104 Phase III Crohn’s Disease Program And Introduces Option For Early Stop For Success In Q2/2017 10/6/2016 10:16:18 AM
RedHill Biopharma (RDHL) Announces Initiation Of Phase II Study With YELIVA In Hepatocellular Carcinoma At Medical University of South Carolina 10/5/2016 9:20:24 AM
RedHill Biopharma (RDHL) And IntelGenx Corp. Announce RIZAPORT Commercialization Term Sheet With Pharmatronic Co. For Korea 9/21/2016 8:40:08 AM
RedHill Biopharma (RDHL) Announces Research Collaboration With Stanford University For YELIVA 9/12/2016 10:55:13 AM
RedHill Biopharma (RDHL) Announces Phase Ib/II Study With YELIVA Initiated For Multiple Myeloma At A Leading U.S. Academic Medical Center 9/8/2016 11:30:20 AM
RedHill Biopharma (RDHL) Announces Approval Of A European Patent Supporting RHB-104 For Multiple Sclerosis 8/29/2016 11:50:32 AM
RedHill Biopharma (RDHL) Provides 2016 Semi-Annual R&D Update 8/11/2016 12:20:23 PM
RedHill Biopharma (RDHL) Announces Last Patient Visit In Phase IIa Study With RHB-104 For Multiple Sclerosis 8/1/2016 10:43:29 AM